Ixico Regulatory News (IXI)

IXICO announces new contract in Huntington's disease

Third pharma customer in this disease expands growing presence in advanced MRI imaging

23 April 2015, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a contract for a third clinical trial in Huntington's disease ('HD') by a new US-based drug development specialty pharmaceutical customer.

The contract is for an early phase trial for a novel treatment where IXICO will be providing a battery of advanced MRI imaging techniques and clinical trial endpoints. 

This follows the announcements in May and November 2014 of contracts awarded and then extended with two top 15 pharmaceutical companies. This third contract extends and consolidates IXICO's presence in, and revenues to be derived from, this important disease area and further expands the Company's track record and capabilities in advanced MRI imaging techniques.

Professor Derek Hill, Chief Executive of IXICO, commented:

'This third contract in Huntington's disease is gratifying recognition of the success of our developing specialisation in both this disease area and in advanced MRI imaging techniques. These growth areas complement our well established position in the provision of similar support for clinical trials in Alzheimer's disease.'

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital health technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including Alzheimer's disease, Huntington's disease, other causes of dementia and Multiple Sclerosis. 

More information is available on www.ixico.com

About HD

HD is a rare genetic neurodegenerative disorder that affects the patient's normal movement, cognition and behaviour. HD is more common in people of Western European descent than in those of Asian or African ancestry, affecting approximately 5-7 people per 100,000 in Western countries. There are currently no effective marketed treatments for HD. Despite its low incidence, interest in developing therapeutics to treat the disease within the pharmaceutical industry is significant with a large number of pharmaceutical and biotechnology companies globally interested in the indication. IXICO has supported important research in the HD indication area since 2007. The Company has worked with key opinion leaders around the world and charitable organisations to characterise biomarkers that could be used in clinical trials to evaluate the effectiveness of novel treatments in development. A battery of outcome measures is emerging from these published studies and other academic work.

Enquiries:

IXICO plc

Derek Hill, CEO

Susan Lowther, CFO

Charles Spicer, VP Corporate Development

+44 20 7691 2089

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

Daniel Stewart & Company (Joint Broker)

Martin Lampshire

David Coffman

+44 207 776 6550

FTI Consulting Limited (Investor Relations)

Simon Conway

Matthew Moss

Ben Atwell

+44 20 3727 1000